19 March 2026

Bimekizumab and risankizumab go head-to-head

3 minute read

One emerged as a standout, delivering superior ACR50 response at 16 weeks, marking a first for a biologic over an IL-23 inhibitor in active PsA.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

Processing...